Full-Time

Senior Director

Quantitative Pharmacology and Pharmacometrics, Immuno-Oncology

Updated on 8/20/2026

Deadline 9/4/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$210.4k - $331.1k/yr

+ Annual bonus + Long-term incentive

H1B Sponsorship Available

Upper Gwynedd Township, PA, USA + 1 more

More locations: Rahway, NJ, USA

Hybrid

Hybrid work arrangement; domestic relocation is supported.

Bachelor's, Master's, PharmD, PhD

Category
Biology & Biotech (1)
Required Skills
Machine Learning
Biostatistics

Get referred to Merck

See people who can refer or advise you

Requirements
  • A Ph.D. in pharmacokinetics/pharmacodynamics, pharmacometrics, mathematics, statistics/biostatistics, chemical/biomedical engineering, or a related discipline, plus at least 10 years of relevant pharmaceutical industry experience.
  • Alternatively, a Master's, PharmD, or equivalent degree, plus at least 15 years of relevant pharmaceutical industry experience and a demonstrated record of increasing responsibility, independence, and leadership in similar roles.
  • Educational background in biopharmaceutics, pharmaceutical sciences, pharmacometrics, chemical or biomedical engineering, mathematics, computational biology, or a related field.
  • Knowledge of oncology therapeutic areas or diseases.
  • Demonstrated ability to lead an interdisciplinary team or task force and/or oversee the work of others.
  • Extensive experience developing quantitative strategies that impact pipeline decisions and expertise in drug development.
  • Ability to influence regulatory strategies, including independently authoring and defending regulatory filings for marketing authorization, such as NDA or MAA submissions.
  • Experience operating in an inclusive, high-performance work environment while fostering collaboration, driving results, and managing ambiguity.
  • Relevant regulatory and quantitative pharmacology experience.
  • Proficiency in written and verbal communication, interdisciplinary collaboration, and problem scoping and planning.
Responsibilities
  • Lead and shape quantitative pharmacology strategy across oncology programs to inform dose selection, trial design, and go/no-go decisions.
  • Develop and implement integrated model-informed drug development strategies across development stages.
  • Ensure modeling strategies align with regulatory expectations and business priorities.
  • Maintain a comprehensive understanding of global regulatory expectations for small molecules, biologics, antibody-drug conjugates, and T-cell engagers.
  • Lead, mentor, and develop a team of QP2 scientists, including performance management, hiring, retention, and talent development.
  • Provide scientific and operational oversight to team members to ensure high-quality and timely deliverables.
  • Contribute to broader QP2 and Oncology leadership initiatives, including talent strategies and organizational priorities.
  • Identify and support resource planning and allocation with senior leadership.
  • Serve as QP2 lead on assigned programs and represent QP2 in cross-functional teams and governance forums.
  • Collaborate with Translational, Clinical, and Biostatistics teams to integrate quantitative insights into development strategies.
  • Partner with preclinical teams to translate nonclinical findings into clinical development plans.
  • Contribute to due diligence for business development and licensing opportunities.
  • Develop and contribute to regulatory strategies, including authoring and reviewing INDs, CSRs, CTD modules, and NDA/BLA submissions.
  • Ensure delivery of high-quality clinical pharmacology and pharmacometric analyses and reports.
  • Represent the company in interactions with regulatory agencies, scientific conferences, and external collaborations.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion, up 5% year over year.
  • INTerpath-001 met RFS and DMFS endpoints on August 19, 2026.
  • Merck will present data and pursue filings, expanding intismeran into more tumors.

What critics are saying

  • Keytruda patents start expiring in 2028, exposing Merck to biosimilar erosion.
  • Gardasil layoffs in North Carolina began May 2026, signaling demand weakness and cost pressure.
  • If intismeran disappoints beyond melanoma, Merck loses its clearest post-Keytruda replacement.

What makes Merck unique

  • Keytruda generated $8.37 billion in Q2 2026, powering Merck’s oncology scale.
  • Merck’s August 19, 2026 intismeran win validates individualized mRNA oncology manufacturing.
  • Merck split Human Health on February 23, 2026, sharpening oncology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.